The University of Chicago Header Logo

Connection

Ayman Al-Hendy to Menorrhagia

Back to Details
This is a "connection" page, showing publications Ayman Al-Hendy has written about Menorrhagia.
Ayman Al-Hendy
Connection Strength
9.437
Menorrhagia
  1. LIBERTY randomized withdrawal study: relugolix combination therapy for heavy menstrual bleeding associated with uterine fibroids. Am J Obstet Gynecol. 2023 12; 229(6):662.e1-662.e25.
    View in: PubMed
    Score: 0.863
  2. A plain language summary of the long-term relugolix combination therapy study for uterine fibroids. J Comp Eff Res. 2023 08; 12(8):e230069.
    View in: PubMed
    Score: 0.856
  3. Efficacy and safety of vilaprisan in women with uterine fibroids: data from the ASTEROID 3 randomized controlled trial. F S Sci. 2023 Nov; 4(4):317-326.
    View in: PubMed
    Score: 0.854
  4. A plain language summary of the safety of relugolix combination therapy and improvement in symptoms in women with uterine fibroids from the LIBERTY 1 and LIBERTY 2 studies. Pain Manag. 2023 Apr; 13(4):205-211.
    View in: PubMed
    Score: 0.845
  5. Quality of life with relugolix combination therapy for uterine fibroids: LIBERTY randomized trials. Am J Obstet Gynecol. 2023 03; 228(3):320.e1-320.e11.
    View in: PubMed
    Score: 0.816
  6. Long-term Relugolix Combination Therapy for Symptomatic Uterine Leiomyomas. Obstet Gynecol. 2022 12 01; 140(6):920-930.
    View in: PubMed
    Score: 0.814
  7. Relugolix Combination Therapy for Uterine Leiomyoma-Associated Pain in the LIBERTY Randomized Trials. Obstet Gynecol. 2022 06 01; 139(6):1070-1081.
    View in: PubMed
    Score: 0.787
  8. An evaluation of relugolix/estradiol/norethindrone acetate for the treatment of heavy menstrual bleeding associated with uterine fibroids in premenopausal women. Expert Opin Pharmacother. 2022 Mar; 23(4):421-429.
    View in: PubMed
    Score: 0.772
  9. Reduction of Heavy Menstrual Bleeding in Women Not Designated as Responders to Elagolix Plus Add Back Therapy for Uterine Fibroids. J Womens Health (Larchmt). 2022 05; 31(5):698-705.
    View in: PubMed
    Score: 0.755
  10. Treatment of Uterine Fibroid Symptoms with Relugolix Combination Therapy. N Engl J Med. 2021 02 18; 384(7):630-642.
    View in: PubMed
    Score: 0.724
  11. Changes in symptom burden and quality of life among women with uterine fibroids receiving relugolix combination therapy: a plain language summary. J Comp Eff Res. 2024 08; 13(8):e230194.
    View in: PubMed
    Score: 0.228
  12. Relugolix combination therapy in Black/African American women with symptomatic uterine fibroids: LIBERTY Long-Term Extension study. Am J Obstet Gynecol. 2024 02; 230(2):237.e1-237.e11.
    View in: PubMed
    Score: 0.218
  13. Standardising outcome reporting for clinical trials of interventions for heavy menstrual bleeding: Development of a core outcome set. BJOG. 2023 10; 130(11):1337-1345.
    View in: PubMed
    Score: 0.210
  14. Linzagolix with and without hormonal add-back therapy for the treatment of symptomatic uterine fibroids: two randomised, placebo-controlled, phase 3 trials. Lancet. 2022 09 17; 400(10356):896-907.
    View in: PubMed
    Score: 0.202
  15. Elagolix Treatment for Up to 12 Months in Women With Heavy Menstrual Bleeding and Uterine Leiomyomas. Obstet Gynecol. 2020 06; 135(6):1313-1326.
    View in: PubMed
    Score: 0.172
  16. Elagolix for Heavy Menstrual Bleeding in Women with Uterine Fibroids. N Engl J Med. 2020 01 23; 382(4):328-340.
    View in: PubMed
    Score: 0.168
  17. Elagolix Alone or With Add-Back Therapy in Women With Heavy Menstrual Bleeding and Uterine Leiomyomas: A Randomized Controlled Trial. Obstet Gynecol. 2018 11; 132(5):1252-1264.
    View in: PubMed
    Score: 0.154
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.